Alcaraz Jumps to 44 Cents on Polymarket After Faria Demolition and Sinner Exit
Carlos Alcaraz jumps to 44 cents on Polymarket after demolishing Faria and Sinner's withdrawal. Is the defending champ underpriced at 44¢, or does wrist risk justify the discount?
Carlos Alcaraz's Polymarket odds have moved 10 cents in 72 hours — a 30% reprice — after a dominant second-round win and the withdrawal of the world number one. Whether 44 cents is a bargain or a fair price for a player five weeks removed from a wrist injury is the question the market is now quietly arguing with itself.
TL;DR
- Alcaraz climbed from 34 cents on September 1 to 44 cents by September 4 at 11:16 UTC on Polymarket, driven by his second-round demolition of Jaime Faria and Jannik Sinner's pre-tournament withdrawal.
- DraftKings prices Alcaraz at 47%, three points above the Polymarket figure, with Alexander Zverev the only other credible threat at 23% (DraftKings) or 21 cents (Polymarket).
- Alcaraz had not played a competitive match since April 4 — 16 weeks off — before this tournament, and a single four-set win, however convincing, does not yet constitute a full bill of health.
- Five matches remain in the draw; the market repriced aggressively on two pieces of good news and may reprice further, or may pause here while watching the wrist.
What the Market Says
At press time, Polymarket's "Will Carlos Alcaraz win the 2026 US Open?" market sits at 44 cents YES / 56 cents NO, with $143,047 in 24-hour volume and a single-day move of +4 cents — itself a snapshot of ongoing repricing after the Faria result.
The three-day arc tells a cleaner story. On September 1, following his first-round win over Safiullin, Alcaraz was trading at 34 cents. By September 4 at 11:16 UTC, he'd reached 44 cents. That is a 10-cent move — roughly a 29% increase in implied probability — in 72 hours. Before the tournament began, Kalshi traders had him at 27%, which means the combined effect of two match wins and Sinner's withdrawal has added approximately 17 percentage points to his implied title probability across venues.
The cross-venue gap is narrow but worth noting. DraftKings currently prices Alcaraz at 47% — four points higher than Polymarket's 44 cents. In a liquid, efficient market, a 3-point gap between two venues on the same underlying event is not screaming arbitrage; it fits comfortably inside normal vig and market-maker spreads. It does, however, suggest that one of the two venues is pricing injury risk slightly more conservatively than the other. The DraftKings number may reflect sharper tennis-market participants, or it may simply be lagging the Polymarket order book in the opposite direction. Neither conclusion is certain from the data alone.
The Case
The bull case for Alcaraz rests on three pillars: the quality of the Faria performance, the cleared field, and the defending-champion premium.
On September 3, Alcaraz faced Jaime Faria, a Portuguese qualifier ranked 72nd. He dropped the first set 6-4 — not ideal for a man returning from a four-month wrist injury — and then proceeded to dismantle the match with a methodical precision that looked less like a comeback story and more like a very good player who'd simply been bored for 40 minutes. He won eight consecutive games. The ATP described his second set — a 6-0 — as "perhaps his best set of his campaign thus far." He closed out sets three and four 6-3, 6-2, finishing in 2 hours 40 minutes with 28 winners and no visible wrist trouble.
The BBC noted that Alcaraz "avoided the prospect of an early US Open exit by fighting back from a set down," which is accurate but undersells what happened after that first set. A comeback that produces eight straight games and what the tour's own media arm calls the best set of the campaign is not a survival story.
The field, meanwhile, has thinned considerably. Jannik Sinner, the reigning champion and world number one, withdrew before the tournament with a right knee injury — eliminating the single player most likely to beat Alcaraz in a final. Novak Djokovic, seeded in the main draw, was eliminated in the first round, which the bracket did not expect and the market was slow to fully absorb. That leaves Alexander Zverev as the primary threat, priced at 21 cents on this same Polymarket market and 23% at DraftKings. Zverev won Roland Garros in Alcaraz's absence and reached the Wimbledon final, so his price is not absurd. But Alcaraz holds more than twice his implied probability at every venue tracking this event.
Alcaraz is two matches from the final with five total remaining. He is the defending champion at this event. He has the best grass-and-hard-court movement on tour. And he has now completed two matches without wrist complications in a slam environment. The path from here to the trophy runs through Zverev or Shelton in the final — neither is a foregone loss.
The math on repricing: the market moved him 30% in three days on two match results and one opponent withdrawal. If he wins two more rounds cleanly, there is a reasonable case his Polymarket odds test 55-60 cents before the final. At 44 cents, the market is pricing approximately a coin-flip with a slight lean toward "something goes wrong." That is not obviously wrong — it is also not obviously right.
Risks
The honest case for the NO side is one word, repeated: wrist.
Alcaraz missed 16 weeks of competitive tennis with a wrist injury. He returned at this event, not a smaller tune-up tournament. He dropped a set to a qualifier ranked 72nd in his first extended run of match stress since April 4. The ATP tour is not a laboratory for injury rehabilitation; a Grand Slam is precisely the wrong environment to discover that the wrist has not fully healed, because by the time you discover it, you are probably already down a set in a quarterfinal.
One four-set match — however dominant sets two through four were — is a data point of one. The wrist has not been tested by a prolonged baseline exchange with Zverev, who hits as heavy as anyone on tour. It has not been tested across a three-day turnaround in New York August heat. These are not hypothetical concerns; they are the standard operating conditions of a Grand Slam quarterfinal and beyond.
The market has already moved 10 cents in 72 hours on good news. If the wrist becomes a story again — even a minor one, a trainer visit, a retirement mid-match — the repricing in the other direction would be at least as sharp. Polymarket's NO side at 56 cents is not a contrarian position; it is the majority of the market's implied belief, and that majority is not being irrational.
Beyond the wrist: Zverev at 21 cents on Polymarket represents a player who won a Major this year and has repeatedly gone deep at slams on hard courts. Ben Shelton at 8 cents is a 13% implied probability at DraftKings — a home-crowd dark horse with a big serve and the kind of unpredictable game that upsets seedings. The draw is not empty below Alcaraz.
Finally, the market may simply be efficient here. A 3-point gap between Polymarket and DraftKings is not a structural mispricing; it is noise. The NO at 56 cents is priced by the same information available to the YES buyer. If you think the market has underpriced the wrist risk, 56 cents is your number. If you think two clean matches and a cleared field justify the defending champion trading below a coin-flip, 44 cents is yours.
Both sides have a case. That is what makes it a market.
Prices captured at press time and are not live. Not financial advice.
Every price in this piece was captured September 4, 2026 at 11:16 UTC. Odds move; the analysis may not age with them. Not financial advice.